Drugs / CHF1535
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT01584505 | Apr → Sep 2012 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT01584492 | Dec 2011 → Feb 2013 | asthma | Chiesi Farmaceutici S.p.A. | Completed | Met primary |
| Phase 2 | NCT01848769 | Sep 2009 → Dec 2010 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07546981 | Jun 2026 → Oct 2028 expected | asthma | Chiesi Farmaceutici S.p.A. | Recruiting | No outcome recorded |
| Phase 3 | NCT01475032 | Sep 2011 → Sep 2012 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT05018598 Comparator | Feb 2022 → Apr 2024 | asthma | Chiesi Farmaceutici S.p.A. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT05097014 Comparator | Oct 2021 → Feb 2023 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHF 1535 | “CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer” NCT01584492 ↗7“to CHF 1535 200/6 μg pMDI (Fixed Combination of Extrafine Formulation of Beclometasone Dipropionate Plus Formoterol Fumarate)” NCT05018598 ↗ “Active Comparator: CHF 1535 100/6 μg pMDI HFA-134a” NCT07546981 ↗ “versus CHF1535 (BDP/FF 200/6 pMDI)” NCT05018598 ↗ |
| Route | Inhaled | “CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer” NCT01584492 ↗ |